A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has gained 7% over this period.

The bioscience industry has been rapidly expanding with research, people, and ideas. This year’s third annual Bioscience Summit brings together those ideologies and more. “We just want to understand ...